80 related articles for article (PubMed ID: 37749034)
1. [Efficacy and safety of programmed death-1 inhibitor in the treatment of relapsed/refractory classical Hodgkin's lymphoma].
Shan DD; Liu HM; Liu W; Huang WY; Lyu R; Deng SH; Yi SH; An G; Xu Y; Sui WW; Wang TY; Fu MW; Zhao YZ; Qiu LG; Zou DH
Zhonghua Xue Ye Xue Za Zhi; 2023 Jul; 44(7):555-560. PubMed ID: 37749034
[No Abstract] [Full Text] [Related]
2. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma.
Armand P; Zinzani PL; Lee HJ; Johnson NA; Brice P; Radford J; Ribrag V; Molin D; Vassilakopoulos TP; Tomita A; von Tresckow B; Shipp MA; Herrera AF; Lin J; Kim E; Chakraborty S; Marinello P; Moskowitz CH
Blood; 2023 Sep; 142(10):878-886. PubMed ID: 37319435
[TBL] [Abstract][Full Text] [Related]
3. [Clinical and pathological characteristics and prognosis analysis of gray zone lymphoma].
Liu SZ; Zong XP; Cai WZ; He HJ; Ma ZX; Li JQ; Li CX; Wu DP
Zhonghua Yi Xue Za Zhi; 2024 Jan; 104(1):69-73. PubMed ID: 38178771
[TBL] [Abstract][Full Text] [Related]
4. Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents.
Spinner MA; Sica RA; Tamaresis JS; Lu Y; Chang C; Lowsky R; Frank MJ; Johnston LJ; Miklos DB; Muffly LS; Negrin RS; Rezvani AR; Shiraz P; Shizuru JA; Weng WK; Binkley MS; Hoppe RT; Advani RH; Arai S
Blood; 2023 Jun; 141(22):2727-2737. PubMed ID: 36857637
[TBL] [Abstract][Full Text] [Related]
5. Real world effectiveness and safety of nivolumab in patients with relapsed or refractory classical hodgkin lymphoma.
Lorente Fernández L; Romero Domínguez S; Albert Marí A; Núñez Benito E; López Briz E; Poveda Andrés JL
Farm Hosp; 2024 Jun; ():. PubMed ID: 38839541
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma.
Liu W; Lin N; Feng X; Xie Y; You C; Zhou X; Song Y; Zhu J
Signal Transduct Target Ther; 2023 Sep; 8(1):356. PubMed ID: 37726266
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade.
Mei M; Chen L; Godfrey J; Song J; Egelston C; Puverel S; Budde LE; Armenian S; Nikolaenko L; Nwangwu M; Guo W; Gao L; Lee P; Chen R; Daniels S; Kennedy N; Peters L; Zain J; Rosen S; Forman S; Popplewell L; Kwak L; Herrera AF
Blood; 2023 Oct; 142(16):1359-1370. PubMed ID: 37339586
[TBL] [Abstract][Full Text] [Related]
8. Selinexor With Anti-PD-1 Antibody as a Potentially Effective Regimen for Patients With Natural Killer/T-Cell Lymphoma Failing Prior L-Asparaginase and PD-1 Blockade.
Tao R; Liu C; Zhang W; Zhu Y; Ma Y; Hao S
Oncologist; 2024 Jan; 29(1):e90-e96. PubMed ID: 37616529
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study.
Wang Y; Yang X; Wang Y; Xue J; Zhang N; Yang X; Cong N; Zhang J; Zhu C; Zhang L; Hou X; Zhao H
Cancer Immunol Immunother; 2023 Jul; 72(7):2197-2204. PubMed ID: 36856834
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.
Rossi C; Gilhodes J; Maerevoet M; Herbaux C; Morschhauser F; Brice P; Garciaz S; Borel C; Ysebaert L; Obéric L; Lazarovici J; Deau B; Dupuis J; Chauchet A; Abraham J; Bijou F; Stamatoullas-Bastard A; Malfuson JV; Golfier C; Laurent C; Pericart S; Traverse-Glehen A; Kanoun S; Filleron T; Casasnovas RO; Ghesquières H
Am J Hematol; 2018 Jun; ():. PubMed ID: 29884994
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.
Shindiapina P; Alinari L
Ther Adv Hematol; 2018 Apr; 9(4):89-105. PubMed ID: 29623180
[TBL] [Abstract][Full Text] [Related]
12. Hodgkin's lymphoma: post- autologous transplantation consolidation therapy.
Merli F; Ballerini F; Botto B; Gotti M; Pavone V; Pulsoni A; Stefani PM; Massaro F; Viviani S
Acta Biomed; 2020 May; 91(S-5):23-29. PubMed ID: 32525131
[TBL] [Abstract][Full Text] [Related]
13. High-dose methotrexate, thiotepa, orelabrutinib combined with or without rituximab in primary or secondary central nervous system diffuse large B-cell lymphoma: a single-center retrospective analysis.
Li Y; Li Y; Zeng R; He Y; Liang L; Ou L; Su C; Zhou H; Xiao L
J Cancer; 2023; 14(17):3182-3190. PubMed ID: 37928429
[No Abstract] [Full Text] [Related]
14. Advances in Hodgkin's lymphoma pharmacotherapy: a focus on histone deacetylase inhibitors.
Ho T; Coleman C; Shah P; Yazbeck V
Expert Opin Pharmacother; 2023; 24(13):1427-1438. PubMed ID: 37249399
[TBL] [Abstract][Full Text] [Related]
15. Association of CD8 + T cells expressing nivolumab-free PD-1 with clinical status in a patient with relapsed refractory classical Hodgkin lymphoma.
Kowata S; Seki Y; Tsukushi Y; Sato T; Asano K; Maeta T; Yashima-Abo A; Sasaki R; Okano Y; Oyake T; Ito S
Int J Hematol; 2023 Dec; 118(6):751-757. PubMed ID: 37488284
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of paediatric refractory Hodgkin lymphoma with immunotherapy - A case report and literature review.
Mogensen N; Cananau C; Ranta S; Karlén J; Kwiecinska A; Baecklund F
Acta Paediatr; 2024 Jul; 113(7):1483-1495. PubMed ID: 38596833
[TBL] [Abstract][Full Text] [Related]
17. [A Real-World Single-Center Study of Adult Hodgkin's Lymphoma].
Wang LL; Tian L; Dong F; Yang P; Wan W; Li QH; Ma L; Gao JJ; Wang JJ; Zhao W; Jing HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):428-433. PubMed ID: 38660847
[TBL] [Abstract][Full Text] [Related]
18. Optimization of immune checkpoint inhibitor treatment planning for relapsed or refractory extranodal NK/T cell lymphoma.
Yoon SE; Cho H; Berning P; Cho J; Kim HY; Yoon DH; Schmit N; Kim SJ; Kim WS
Ann Hematol; 2024 May; ():. PubMed ID: 38730207
[TBL] [Abstract][Full Text] [Related]
19. Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States.
Lurain K; Zarif TE; Ramaswami R; Nassar AH; Adib E; Abdel-Wahab N; Chintapally N; Drolen CE; Feldman T; Haykal T; Nebhan CA; Kambhampati S; Li M; Mittra A; Lorentsen M; Kim C; Drakaki A; Morse M; Johnson DB; Mangla A; Dittus C; Ravi P; Baiocchi RA; Chiao EY; Rubinstein PG; Yellapragada SV; LaCasce AS; Sonpavde GP; Naqash AR; Herrera AF
Clin Lymphoma Myeloma Leuk; 2024 Apr; ():. PubMed ID: 38714474
[TBL] [Abstract][Full Text] [Related]
20. An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin's lymphoma.
Yang L; Zhao Q; Chen T; Liu W; Qiu X; Chen J; Huang S; Huang R; Dong L
Clin Exp Med; 2023 Nov; 23(7):3767-3780. PubMed ID: 37106265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
